Vyvanse Approved for ADHD
The Carlat Psychiatry Report, Volume 5, Number 4, April 2007
https://www.thecarlatreport.com/newsletter-issue/tcprv5n4/
Issue Links: Learning Objectives | Editorial Information
Topics: ADHD
Louann Brizendine, MD
On February 23, the FDA approved Shire and New River’s Vyvanse (lisdexamfetamine dimesylate) for the treatment of ADHD in children. Vyvanse is the molecule dextroamphetamine (trade names Dexedrine and Dextrostat) attached to the amino acid lysine.
You can't view details of this content, please login or buy subscription here
Louann Brizendine, MD
Founder, UCSF Women’s Mood and Hormone Clinic Lynne and Marc Benioff Clinical Professor of Psychiatry Author, The Female Brain
Dr. Brizendine has disclosed that she has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity. The author has disclosed that the estradiol patch has not been approved by the U.S. Food and Drug Administration for use in the treatment of depression. Please consult product labeling for the approved usage of this drug.